Table 2

Experimental schedules for the study of the antagonist effects of nor-BNI against systemic U50,488 and bremazocine

Experiment 1Experiment 2Experiment 3
BaselineU50,488 & bremazocineU50,488 & bremazocineU50,488 & bremazocine
Pretreatment  conditions     Days after nor-BNI injection i.c. nor-BNI 0.32 mgi.c. nor-BNI 0.032 mgs.c. nor-BNI 0.32 mg in the back
1U50,488U50,488U50,488
3BremazocineBremazocineBremazocine
7U50,488U50,488U50,488
10BremazocineBremazocineBremazocine
14U50,488U50,488
21U50,488U50,488
28BremazocineBremazocine
35U50,488U50,488
42Bremazocine
49U50,488
56Bremazocine
63U50,488